Au centre en rouge le Dr Revital Rattenbach, CEO de 4PPharma

France-Israel: 4P-Pharma, SATT Aquitaine and Bordeaux University to develop an anti-cancer drug. Video

4P-Pharma has signed an exclusive license agreement with Aquitaine Science Transfert, for the development of a drug targeting pancreatic cancer, triple negative breast cancer...

Read more

Israël Science Info